Synthesis and antiplasmodial and antimycobacterial evaluation of new nitroimidazole and nitroimidazooxazine derivatives.

The synthesis and antiplasmodial and antimycobacterial evaluation of two new series of nitroimidazole and nitroimidazooxazine derivatives is described. The majority of these compounds, especially hybrids 9d, 9f, and 14b, exhibited potent activity against the chloroquine-resistant K1 strain of Plasmodium falciparum. Furthermore, a notable number from the tetrazole series were significantly more active against M. tuberculosis than kanamycin, a standard TB drug.

[1]  J. Gut,et al.  The design, synthesis, in silico ADME profiling, antiplasmodial and antimycobacterial evaluation of new arylamino quinoline derivatives. , 2012, European journal of medicinal chemistry.

[2]  J. Flynn,et al.  Metronidazole prevents reactivation of latent Mycobacterium tuberculosis infection in macaques , 2012, Proceedings of the National Academy of Sciences.

[3]  W. Denny,et al.  Structure-activity relationships for amide-, carbamate-, and urea-linked analogues of the tuberculosis drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824). , 2012, Journal of medicinal chemistry.

[4]  Kelly Chibale,et al.  The state of the art in anti-malarial drug discovery and development. , 2011, Current topics in medicinal chemistry.

[5]  Eric Arnoult,et al.  The challenge of new drug discovery for tuberculosis , 2011, Nature.

[6]  K. Srivastava,et al.  Synthesis of new 4-aminoquinolines and quinoline-acridine hybrids as antimalarial agents. , 2010, Bioorganic & medicinal chemistry letters.

[7]  W. Denny,et al.  Synthesis and Structure−Activity Relationships of Aza- and Diazabiphenyl Analogues of the Antitubercular Drug (6S)-2-Nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824) , 2010 .

[8]  W. Denny,et al.  The nitroimidazooxazines (PA-824 and analogs): structure-activity relationship and mechanistic studies. , 2010, Future medicinal chemistry.

[9]  J. Bayona,et al.  Multidrug-resistant and extensively drug-resistant tuberculosis: a threat to global control of tuberculosis , 2010, The Lancet.

[10]  W. Burman.  Rip Van Winkle wakes up: development of tuberculosis treatment in the 21st century. , 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[11]  S. Pricl,et al.  Antiviral activity of benzimidazole derivatives. II. Antiviral activity of 2-phenylbenzimidazole derivatives. , 2010, Bioorganic & medicinal chemistry.

[12]  W. Denny,et al.  Synthesis and structure-activity studies of biphenyl analogues of the tuberculosis drug (6S)-2-nitro-6-{[4-(trifluoromethoxy)benzyl]oxy}-6,7-dihydro-5H-imidazo[2,1-b][1,3]oxazine (PA-824). , 2010, Journal of medicinal chemistry.

[13]  R. Marks,et al.  Synthesis, characterization and protein binding properties of supported dendrons , 2009 .

[14]  Ramandeep Singh,et al.  Structure−Activity Relationships of Antitubercular Nitroimidazoles. 1. Structural Features Associated with Aerobic and Anaerobic Activities of 4- and 5-Nitroimidazoles , 2009 .

[15]  E. Chan,et al.  Multidrug-resistant and extensively drug-resistant tuberculosis: a review , 2008, Current opinion in infectious diseases.

[16]  P. Nadol,et al.  Provider-initiated HIV testing and counseling in TB clinical settings: tools for program implementation. , 2008, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[17]  P. V. van Helden,et al.  Drug resistance in Mycobacterium tuberculosis. , 2006, Current issues in molecular biology.

[18]  Ping Chen,et al.  Identification of a new antitubercular drug candidate, SQ109, from a combinatorial library of 1,2-ethylenediamines. , 2005, The Journal of antimicrobial chemotherapy.

[19]  P. Brennan.  Structure, function, and biogenesis of the cell wall of Mycobacterium tuberculosis. , 2003, Tuberculosis.

[20]  Silvio Massa,et al.  Synthesis, biological evaluation, and binding mode of novel 1-[2-(diarylmethoxy)ethyl]-2-methyl-5-nitroimidazoles targeted at the HIV-1 reverse transcriptase. , 2002, Journal of medicinal chemistry.

[21]  Rachel L. Edwards,et al.  The Medicinal Chemistry of Tuberculosis Chemotherapy , 2011 .

[22]  D. Mitchison,et al.  Comparison of the sterilising activities of the nitroimidazopyran PA-824 and moxifloxacin against persisting Mycobacterium tuberculosis. , 2008, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.